Skip to main content
Disc Medicine, Inc. logo

Disc Medicine, Inc. — Investor Relations & Filings

Ticker · IRON ISIN · US36870G1058 US Manufacturing
Open in API
Filings indexed 690 across all filing types
Latest filing 2022-11-03 Regulatory Filings
Country US United States of America
Listing US IRON

About Disc Medicine, Inc.

https://www.discmedicine.com/

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with serious hematologic diseases. The company's research focuses on fundamental pathways of red blood cell biology to address a range of disorders. Its pipeline includes bitopertin, an investigational therapy for erythropoietic protoporphyria (EPP) for which a New Drug Application has been submitted for accelerated approval. Other clinical-stage programs are evaluating treatments for myelofibrosis-associated anemia and other conditions involving ineffective erythropoiesis.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter from Gemini Therapeutics, Inc. responding to comments from the SEC staff regarding an Amendment No. 1 to a Registration Statement on Form S-4. The letter discusses revisions made to the Registration Statement, including financial analyses, projections, and disclosures related to a merger. The document references the Registration Statement on Form S-4, which is a filing related to securities registration, often for mergers or acquisitions. The content is focused on addressing SEC comments on the registration statement rather than presenting financial results, management changes, or other report types. The letter is a regulatory correspondence responding to SEC comments on a registration statement amendment, which fits best under Regulatory Filings (RNS) as it does not itself constitute the registration statement or a financial report but is a regulatory communication related to it.
2022-11-03 English
Regulatory Filings 2022
Regulatory Filings
2022-11-01 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Gemini Therapeutics, Inc. It announces a merger agreement and the initiation of a clinical study by a subsidiary. It includes a press release and social media posts as exhibits. The document is primarily an announcement of corporate events and related disclosures, not a full financial report or detailed management discussion. It references future filings such as a proxy statement on Form S-4 but does not contain financial statements or detailed financial analysis itself. The document is over 12,000 characters but is an event-driven regulatory filing rather than a report like a 10-K or 10-Q. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2022-10-31 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Gemini Therapeutics, Inc. It includes disclosures about a merger agreement and the initiation of a Phase 2 clinical study by a subsidiary. The document contains detailed information about the merger, forward-looking statements, and references to other filings such as a Form S-4 registration statement and proxy materials. It also includes exhibits like a press release and social media posts. The content is primarily an announcement of corporate events and regulatory disclosures rather than a full financial report or earnings release. The Form 8-K is a regulatory filing used to report major events that shareholders should know about. Given the nature of the document as a current report disclosing material corporate events and regulatory information, the appropriate classification is Regulatory Filings (RNS). The document is lengthy (15,000 characters) and contains substantive information, but it is not an annual or quarterly report, audit report, earnings release, or other specific report type. Therefore, Regulatory Filings (RNS) is the best fit with high confidence.
2022-10-31 English
GEMINI THERAPEUTICS, INC.
Major Shareholding Notification
2022-10-27 English
FORM 4
Director's Dealing
2022-10-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.